JPWO2019241503A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019241503A5
JPWO2019241503A5 JP2020569002A JP2020569002A JPWO2019241503A5 JP WO2019241503 A5 JPWO2019241503 A5 JP WO2019241503A5 JP 2020569002 A JP2020569002 A JP 2020569002A JP 2020569002 A JP2020569002 A JP 2020569002A JP WO2019241503 A5 JPWO2019241503 A5 JP WO2019241503A5
Authority
JP
Japan
Prior art keywords
dose
aminosterol
pharmaceutical composition
subject
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020569002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527090A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036946 external-priority patent/WO2019241503A1/fr
Publication of JP2021527090A publication Critical patent/JP2021527090A/ja
Publication of JPWO2019241503A5 publication Critical patent/JPWO2019241503A5/ja
Pending legal-status Critical Current

Links

JP2020569002A 2018-06-13 2019-06-13 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 Pending JP2021527090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684496P 2018-06-13 2018-06-13
US62/684,496 2018-06-13
PCT/US2019/036946 WO2019241503A1 (fr) 2018-06-13 2019-06-13 Méthodes et compositions pour traiter et/ou prévenir la progression et/ou l'apparition de la neurodégénérescence liée à l'âge

Publications (2)

Publication Number Publication Date
JP2021527090A JP2021527090A (ja) 2021-10-11
JPWO2019241503A5 true JPWO2019241503A5 (fr) 2022-04-22

Family

ID=68838925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569002A Pending JP2021527090A (ja) 2018-06-13 2019-06-13 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物

Country Status (11)

Country Link
US (2) US20190381071A1 (fr)
EP (1) EP3806862A4 (fr)
JP (1) JP2021527090A (fr)
KR (1) KR20210009422A (fr)
CN (1) CN112566641A (fr)
AU (1) AU2019285065A1 (fr)
BR (1) BR112020025296A2 (fr)
CA (1) CA3103463A1 (fr)
MX (1) MX2020013614A (fr)
SG (1) SG11202012343TA (fr)
WO (1) WO2019241503A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028791A1 (fr) * 2018-08-03 2020-02-06 Enterin Laboratories Formes posologiques d'aminostérol intranasale à faible dosage et procédés d'utilisation associés
EP3829587A4 (fr) * 2018-08-03 2022-07-20 Enterin, Inc. Compositions et méthodes pour traiter des troubles de l'axe intestin-cerveau
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
CN110827282B (zh) * 2020-01-13 2020-04-10 南京慧脑云计算有限公司 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统
CN111110873A (zh) * 2020-02-24 2020-05-08 苏州欣影生物医药技术有限公司 一种磁共振/核医学双模态分子影像探针的制备方法
CN111528839B (zh) * 2020-05-29 2023-06-23 北京京东方健康科技有限公司 睡眠检测方法和装置、助眠设备和方法
AU2021446815A1 (en) * 2021-05-21 2023-12-14 Animuscure Inc. Composition comprising inotodiol for prevention or treatment of muscular disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
EP3293195A1 (fr) * 2007-09-06 2018-03-14 OHR Pharmaceutical, Inc. Composés destinés à être utilisés dans le traitement du diabète
US8623416B2 (en) * 2009-11-25 2014-01-07 Michael Zasloff Formulations comprising aminosterols
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Similar Documents

Publication Publication Date Title
JP2021527090A (ja) 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物
JP2022003085A (ja) 神経変性疾患のための治療薬
JP7352542B2 (ja) 運動失調を処置するためのリルゾールプロドラッグの使用
AU2020324937A1 (en) Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same
US20230372335A1 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
EP3829587A1 (fr) Compositions et méthodes pour traiter des troubles de l'axe intestin-cerveau
JPWO2019241503A5 (fr)
Nicoletti et al. Treatment with dimethyl fumarate enhances cholinergic transmission in multiple sclerosis
US20210260078A1 (en) Low dosage intranasal aminosterol dosage forms and methods of using the same
US20200038420A1 (en) Aminosterol compositions and methods of using the same for treating depression
CN116134048A (zh) 用于治疗神经精神障碍的组合物和方法
De Pasqua Myotonic syndromes: analysis of factors with pathogenetic and prognostic significance
WO2019226080A1 (fr) Médicament pour traiter des troubles d'une fonction d'organe ou de tissu et maladies accompagnées de tels troubles, et son procédé d'obtention
US20210315907A1 (en) Compositions and methods for treating brain-gut disorders
WO2023007320A1 (fr) Lemborexant destiné à être utilisé dans des procédés de traitement d'un trouble du rythme sommeil/réveil et de troubles du rythme circadien associés à des maladies neurodégénératives
US20200038416A1 (en) Methods of treating cardiac conduction defects using aminosterol compositions
US20200038417A1 (en) Methods and compositions for treating cognitive impairment
US20050233976A1 (en) Therapeutic methods
WO2023239908A1 (fr) Traitement de maladies mitochondriales avec le stimulateur de la sgc pénétrant dans le snc tel que le zagociguat
St. Louis To sleep, perchance to seize: the odd marriage of sleep and epilepsy
Byrne et al. Reversible Dementia and Apparent Brain Atrophy During Valproate Therapy